NEVPF (Abliva AB) Short Interest

View and export this data going back to 2014. Start your Free Trial

What is Abliva AB Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Abliva AB's Short Interest

For the Biotechnology subindustry, Abliva AB's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abliva AB's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abliva AB's Short Interest distribution charts can be found below:

* The bar in red indicates where Abliva AB's Short Interest falls into.

Abliva AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OTCPK:NEVPF) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

ABLI:Sweden 0QDU:UK NTP:Germany

Address

Scheeletorget 1, Medicon Village, Lund, SWE, 223 81

Website

https://www.abliva.com

Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase. . The company is focused on two projects. KL1333, a powerful NAD+ and NADH regulator, in late-stage development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement therapy, has just completed preclinical development.